Sascha Alilovic
Partner @ SHS Capital
Munich, Germany
Sascha Alilovic is a Series B investor at SHS Capital in Munich focused on Health Care and Therapeutics. Sascha Alilovic has been a Partner at SHS since 2018 and was previously a Venture Partner. Prior to that, he was head of corporate finance & corporate development at MorphoSys AG and head of complex corporate transactions at Siemens and various corporate finance boutiques. Sascha Alilovic holds a degree in economics from EBS University ofEconomics and Law and a Bachelor of Science degree in Computer Science.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Sascha Alilovic invests in
Stages Sascha Alilovic invests in
Countries Sascha Alilovic invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (40%)
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Medical Device 2 (40%)
- Medical 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- France 1 (20%)
- Slovenia 1 (20%)
- The Netherlands 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M / Series B / May 27, 2025 | ||
| We help clinicians provide better medical assessment in less time! The MESI mTABLET is an FDA/CE marked predictive medical assessment platform for ambulatory healthcare with extensive AI and marketplace capabilities. | $19.7M / Venture - Series Unknown / Jun 22, 2023 | ||
| PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M / Series B / Nov 09, 2021 | ||
| PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $17.4M / Series B / Nov 09, 2021 | ||
| Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $31M / Series A / Sep 22, 2020 |
Co-Investors
About SHS Capital
SHS is an independent private equity company. Their focus is on investments in the MedTech, Life Sciences, Diagnostics, and Digital Health sectors.
SHS Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andre Zimmermann
Partner
|
|||
|
Sascha Alilovic
Partner
|
|||
David Wehner
Senior Investment manager
|
|||
Federico Bursgens
Limited Partner
|
|||
Friedrich Baldinger
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sascha Alilovic invest in?
Sascha Alilovic invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sascha Alilovic?
Public channels for Sascha Alilovic include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sascha Alilovic last invest?
The most recent investment recorded for Sascha Alilovic closed in May 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
